反応式
[CH:1]([C:4]1[N:8]=[C:7]([N:9]2[CH2:14][CH2:13][CH:12]([OH:15])[CH2:11][CH2:10]2)[O:6][N:5]=1)([CH3:3])[CH3:2].[H-].[Na+].Cl[C:19]1[N:24]=[CH:23][N:22]=[C:21]2[N:25]([C:28]3[CH:33]=[CH:32][C:31]([S:34]([CH3:37])(=[O:36])=[O:35])=[CH:30][C:29]=3[F:38])[N:26]=[CH:27][C:20]=12.O>C1COCC1>[F:38][C:29]1[CH:30]=[C:31]([S:34]([CH3:37])(=[O:35])=[O:36])[CH:32]=[CH:33][C:28]=1[N:25]1[C:21]2=[N:22][CH:23]=[N:24][C:19]([O:15][CH:12]3[CH2:11][CH2:10][N:9]([C:7]4[O:6][N:5]=[C:4]([CH:1]([CH3:3])[CH3:2])[N:8]=4)[CH2:14][CH2:13]3)=[C:20]2[CH:27]=[N:26]1参加物
6
反応物 4
生成物 1
試薬・触媒・溶媒 1
実験手順
1-(3-Isopropyl-[1,2,4]oxadiazol-5-yl)-piperidin-4-ol (338 mg, 1.6 mmol) and sodium hydride (87 mg, 3.66 mmol) were stirred together in dry THF (2 mL) at room temperature for 30 minutes. 4-Chloro-1-(2-fluoro-4-methanesulfonyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidine was then added and the reaction continued to stir at room temperature for 45 minutes. Its progress was monitored by thin layer chromatography and LCMS. The reaction was treated with water and the desired compound was extracted with ethyl acetate. Organic layer was evaporated in vacuo. Purification by HPLC provided the desired Compound A198 as a white solid (600 mg, 98%). Exact mass calculated for C22H24FN7O4S 501.53, found 502.2 (MH+).
後処理
- extractionthe desired compound was extracted with ethyl acetate
- customOrganic layer was evaporated in vacuo
- customPurification by HPLC
出典と根拠
- ORDレコード
- ord-72693c33d2ad4afaad578e55bd8b3c5d
- 出典データセット
- uspto-grants-2006_11
- 特許番号
- US07132426B2
関連ノート
読み込み中…